Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

13.3%

2 terminated/withdrawn out of 15 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

27%

4 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

5(41.7%)

Phase 3

2(16.7%)

N/A

2(16.7%)

Phase 4

2(16.7%)

Phase 2

1(8.3%)

12Total

Phase 1(5)

Phase 3(2)

N/A(2)

Phase 4(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT05947656Not ApplicableRecruiting

Evaluation of the NaviFUS System in Drug Resistant Epilepsy

Role: collaborator

NCT06886620Phase 3Terminated

Assess the Safety and Effectiveness of Once Daily PMR Compared to Twice Daily Pletaal® in Patients With Intermittent Claudication

Role: lead

NCT05191862Phase 1Terminated

Bioequivalence Study of PMR Compared to Cilostazol IR Tablets in Healthy Volunteers

Role: lead

NCT06167265Phase 1Completed

BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers

Role: lead

NCT05466734Phase 1Completed

BE Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

Role: lead

NCT03864666Phase 1Completed

Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

Role: lead

NCT03480321Phase 1Completed

Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

Role: lead

NCT02949349Phase 2Completed

Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis

Role: lead

NCT01261169Unknown

Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study

Role: lead

NCT00541554Phase 4Unknown

Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia

Role: lead

NCT00541437Completed

Type 2 Diabetes Patients Switched From Sulfonylurea With Metformin to Glyburide/Metformin Combination Tablet

Role: lead

NCT00541502Unknown

Improving Cognitive Function of Aripiprazole in Treating Adolescents and Young Adults With Psychotic Disorder

Role: lead

NCT00244231Phase 3Completed

Efficacy and Safety Study of Nidadd in the Management of Hyperlipidemia

Role: lead

NCT00442312Phase 4Unknown

Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy

Role: lead

NCT00262184Not ApplicableUnknown

A Taiwan Isoflavone Multicenter Study (TIMS)

Role: collaborator

All 15 trials loaded